Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PU8Z
|
|||
| Former ID |
DCL000511
|
|||
| Drug Name |
Dacetuzumab
|
|||
| Synonyms |
SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3] | Terminated | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Terminated | [1] | ||
| Company |
Roche; Genentech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | |||
| REF 2 | A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.Leuk Lymphoma.2010 Feb;51(2):228-35. | |||
| REF 3 | Agonistic CD40 antibodies and cancer therapy | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.